Transforming The Management Of Critical Bleeding and Clotting

HemoSonics is bringing to market a next-generation point-of-care diagnostic platform, the Quantra, that provides actionable information to guide the management of critical bleeding and clotting.

Our goal is to improve outcomes and reduce healthcare costs by enabling more targeted selection and dosing of blood products in critical settings. We seek to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely and accurate information on coagulation status at the point of care, enabling clinicians to rapidly choose the right treatment, dramatically improving outcomes and lowering treatment costs.

Our Products

The Quantra™ is a rapid, easy-to-use, point-of-care diagnostic platform that fully characterizes and guides the management of critical bleeding.
Learn more.

Our Technology

Our patented SEER sonorheometry technology quantifies coagulation by measuring the evolving stiffness of clotting blood.
Learn more.

Our Leadership

Our team has a proven track record of successfully developing and bringing to market innovative medical devices.
Learn more.

Blood cells

Studies show that use of comprehensive point-of-care coagulation testing in surgical settings leads to:

Improved clinical outcomes

  • Fewer transfusions
  • Fewer complications

Reduced cost of care

  • Reduced blood product utilization
  • Shorter inpatient stays

NEWSFEED

Four Quantra Abstracts Presented at ISTH 2017

Charlottesville, VA – July 11, 2017– HemoSonics today announced the presentation of scientific and clinical data at the XXVI International Society on Thrombosis and Hemostasis (ISTH) Congress in Berlin, Germany.  These abstracts demonstrate the excellent analytical performance of the Quantra Surgical Cartridge  with the Quantra™ Hemostasis Analyzer and its clinical utility in cardiac surgery and cancer patients. The data is being presented by Clinicians at the University of Virginia and associates at HemoSonics LLC.  The ISTH conference is being held in Berlin, Germany, July 8-13, 2017. The Quantra System is designed for use in critical care settings which require that results be generated quickly from an instrument that is easy to operate at the point of care.   The studies demonstrate that the Quantra Surgical Cartridge provides precise assessment of four key coagulation parameters within 15 minutes, using the automated Quantra Hemostasis Analyzer. The abstract “Comparison of Arterial and Venous Coagulation Parameters Measured with the Quantra™ System in Cardiac Surgery” describes a pilot study conducted at the University of Virginia in Charlottesville, VA which compared Quantra coagulation in venous and arterial blood samples. The results showed that Quantra clot stiffness-based parameters (CS, FCS, PCS) were unaffected by sampling site, whereas the clot time-based parameters (CT, CTH) showed good correlation in the presence of minimal bias. In addition, the abstract “Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry to Identify Hypercoagulability in Patients with Cancer” describes the results of a study, also conducted at the University of Virginia, comparing coagulation function in 20 treatment-naïve patients with a new diagnosis of a solid tumor to 30 normal controls. The results demonstrated the ability of... read more

Stago Group acquires HemoSonics LLC

The Stago group announced today that it has completed the acquisition of HemoSonics LLC, a company specialized in the development of innovative Point-of-Care testing solutions based in Charlottesville, VA, with facilities in Durham, NC (USA). With the acquisition of the patented SEER technology (Sonic Estimation of Elasticity via Resonance) and its associated QuantraTM Hemostasis Analyzer, Stago demonstrates its willingness to develop a Point-of-Care offering to complete its leadership in Haemostasis testing and beyond. This transaction provides Stago with expanded opportunities for future growth and is an important part of the company’s on-going efforts to diversify its portfolio of medical devices in an ever-changing healthcare environment. “This significant step makes us very proud to contribute to the management of healthcare costs and to the improvement of patients outcomes worldwide,” says Lionel Viret, Chairman of the Board. “Stago brings exceptional expertise in the field of Thrombosis and Hemostasis that will greatly advance our efforts to rapidly and effectively deliver a new standard of care for the management of bleeding in the critical care setting,” says Timothy Fischer, President and Chief Executing Officer of HemoSonics. Ferghana Partners acted as exclusive financial advisor to HemoSonics for this transaction. About Stago Leading player in the In-Vitro Diagnostics industry dedicated to the exploration of Thrombosis and Haemostasis, Stago develops and markets automated systems for blood analysis in coagulation. Created in 1945, Stago is fully dedicated to Haemostasis since 1962. Privately-owned and independent, Stago is headquartered in Asnières, France, with R&D, manufacturing and logistics activities mainly in Europe. Its products are available in 115 countries through a network of 20 subsidiaries and 94 distributors. Stago Group’s... read more

Anesthesia & Analgesia Profiles Quantra’s SEER Technology in Article of the Month and Podcast

Charlottesville, VA  – December 7, 2016 – The editorial staff of Anesthesia & Analgesia has chosen the article “A Novel Device for the Evaluation of Hemostatic Function in Critical Care Settings,” which details the Quantra™ Hemostasis Analyzer, as its Article of the Month featured on the journal’s home page. The article introduces the Quantra analyzer and the Surgical Cartridge and presents the results of analytical performance testing using a research version of the Quantra. These results demonstrate the ability of the Quantra and the Surgical Cartridge to rapidly and comprehensively characterize the key functional components of hemostasis. In addition, OpenAnesthesia.org has conducted a podcast with Dr. Francesco Viola, Founder and Chief Scientific Officer of HemoSonics, about the article and the Quantra Hemostasis Analyzer. The interview can be found at: http://www.openanesthesia.org/article-of-the-month/ Contact Megan Shaw HemoSonics 434.260.0682... read more

Abstract on SEER Technology to be Presented at PGA

Charlottesville, VA – December 6, 2016– HemoSonics today announced the upcoming presentation of data at the Post Graduate Assembly in Anesthesiology (PGA) Meeting demonstrating the potential of the Quantra™ Hemostasis Analyzer to aid clinicians in identifying the need for transfusion of allogeneic blood products in major spine surgery. The conference will be held in New York, NY December 9 – 13, 2016. The reported study was conducted at the University of Virginia in Charlottesville, VA and compared results obtained with a research version of the Quantra™ Hemostasis Analyzer to equivalent rotational thromboelastometery (ROTEM™) and conventional laboratory parameters. The abstract “Predicting Cryoprecipitate and Platelet Transfusion During Major Spine Surgery with SEER Sonorheometry versus Rotational Thromboelastometry” authored by Dr. Bhiken Naik, Dr. Marcel Durieux, and Dr. Edward Nemergut, all faculty in the Department of Anesthesiology at the University of Virginia, showed significant differences in the Quantra measurements of Clot Stiffness, Platelet Contribution and Fibrinogen Contribution between the patients that received a transfusion and those that did not. The area under the Receiver Operative Curves (ROC), a measure of the performance of a diagnostic test, for Fibrinogen Contribution versus cryoprecipitate transfusion, Clot Stiffness versus cryoprecipitate-platelet transfusion, and Platelet Contribution versus platelet transfusions were 0.8, 0.79, and 0.8, respectively. These data indicate that the Quantra and SEER Sonorheometry may provide clinically relevant measurements that could be utilized to aid in the management of perioperative bleeding. Abstract Details Title: Predicting Cryoprecipitate and Platelet Transfusion During Major Spine Surgery with SEER Sonorheometry versus Rotational Thromboelastometry Authors: Naik, BI, Durieux, ME, Nemergut, EC Date: December 11, 2016, 9:30am Board:  P-9092 Contact Megan Shaw HemoSonics 434.260.0682... read more

PennsylvaniaBIO